View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsRace Oncology 향후 성장Future 기준 점검 2/6Race Oncology은 연간 수입과 매출이 각각 0.1%와 34.8% 증가할 것으로 예상되고 EPS는 연간 40.2%만큼 감소할 것으로 예상됩니다.핵심 정보0.1%이익 성장률-40.20%EPS 성장률Biotechs 이익 성장25.3%매출 성장률34.8%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트29 Sep 2024최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 05Race Oncology Limited Announces Change of Chief Medical Officer, Effective May 5, 2025Race Oncology Limited announced the appointments of Dr. Jose Iglesias, who succeeds Dr. Michelle Rashford as Chief Medical Officer (CMO), effective 5 May 2025. Dr. Jose Iglesias is an internationally recognized pharmaceutical executive with a distinguished career spanning both major and emerging pharmaceutical companies. His appointment marks a significant addition to Race's clinical leadership team. Dr. Iglesias held key leadership roles at Abraxis BioScience, including Vice President of Global Clinical Development and Chief Medical Officer, where he oversaw the global development of the reformulated chemotherapeutic agent, Abraxane® (paclitaxel) and other pipeline assets. He later served as Vice President of Clinical Development at Celgene, successfully leading several Phase 3 clinical programs for Abraxane® in pancreatic, lung, and metastatic breast cancers. Dr. Iglesias has also held senior medical leadership roles at Amgen, Bionomics, Biothera Pharmaceuticals, Apobiologix, and Eli Lilly, including as Head of Clinical Studies at Eli Lilly Australia. His has extensive experience interacting with global regulatory authorities, reimbursement agencies, oncology cooperative groups, and patient advocacy organizations. He serves as an independent oncology consultant, specializing in solid tumour oncology, immuno-oncology, and translational medicine, with a focus on early to mid-phase clinical development. A widely published expert in oncology, Dr. Iglesias's work has garnered over 12,000 citations.공시 • Apr 03Race Oncology Limited Announces RC220 Phase 1 Trial Opens for Patient EnrolmentRace Oncology Limited (Race) announced the site activation of Southside Cancer Care Centre (Miranda, NSW) after receiving governance approval enabling the commencement of patient enrolment for its Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumours patients. This follows the receipt of human ethics approval, undertaking site initiation, and completion of all documentation. The Phase 1 trial will be open label and conducted across multiple sites in Australia, Hong Kong and South Korea. The trial will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose (MTCD) in combination with doxorubicin, and effects on a range of clinical biomarkers including m6A RNA. After an interim analysis of the data, the optimal dosage of RC220 in combination with doxorubicin will be assessed in an additional 20 patients for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. The Phase 1 trial will use a Bayesian design enabling greater trial flexibility and speed than traditional approaches. A recent meta-analysis of single agent doxorubicin treatment undertaken by Race Oncology has identified an anticancer response rate to doxorubicin of up to 35% in a wide range of advance and metastatic solid tumour cancers including breast cancer, small cell lung cancer, ovarian cancer, bladder cancer, liver cancer, endometrial cancer, upper gastrointestinal cancer, thyroid cancer, non-small cell lung cancer, and prostate cancer. Preclinical studies by Race Oncology have identified enhancement of the cancer killing activity of doxorubicin by the active anticancer agent in RC220 in 85% of 143 diverse cancer cell lines screened. Timing of first patient enrolment is subject to patient suitability and their interest in participating in the trial.공시 • Mar 31Race Oncology Limited Receives HREC Approval from Bellberry to Commence its RC220 Phase 1 Clinical Trial at Gosford and Wyong HospitalsRace Oncology Limited announced that it has received HREC approval from Bellberry to commence its RC220 Phase 1 clinical trial at Gosford and Wyong Hospitals (Central Coast Local Health District). HREC approval allows both the Gosford and Wyong Hospitals to enrol patients subject to final site approvals and activation. These approvals are expected during the month of April. The RAC-010 clinical trial is designed to assess the safety, tolerability and pharmacokinetics (PK) of RC220 alone and in combination with doxorubicin, in patients with solid tumours. This approval follows recent HREC approval for the Southside Cancer Centre (Miranda). It is expected HREC approval will be received for additional trial sites in Australia, Hong Kong and South Korea over the following months.공시 • Oct 07Race Oncology Limited, Annual General Meeting, Nov 25, 2024Race Oncology Limited, Annual General Meeting, Nov 25, 2024. Location: at the dixon room, state library nsw, 1 shakespeare place, new south wales, australia., sydney Australia공시 • Nov 22Race Oncology Limited Appoints Daniel Tillett as Chief Executive OfficerRace Oncology Limited announced that Dr Daniel Tillett has been appointed full-time Chief Executive Officer, effective immediately. Dr Tillett will work alongside Executive Director, Dr Pete Smith, to advance the Company's strategic, clinical and commercialization plans for bisantrene. From September 2019 to March 2023, Dr Tillett was Race's Chief Scientific Officer and Executive Director. He has most recently been working with the Company in a consultancy capacity. In addition to his extensive experience with Race and bisantrene, Dr Tillett brings more than 25 years of experience in the biotech industry and is the founder and CEO of Nucleics, an Australian biotechnology company focused on DNA sequencing and genomics. He was a tenured academic (Senior Lecturer) within the School of Pharmacy and Applied Science at La Trobe University, Australia teaching and researching in the areas of phage therapy (bacterial virology), pharmacy, environmental microbiology, bioinformatics and cancer.공시 • Oct 10Race Oncology Limited, Annual General Meeting, Nov 27, 2023Race Oncology Limited, Annual General Meeting, Nov 27, 2023, at 12:00 AUS Eastern Standard Time. Location: the Dixon Room, State Library NSW, 1 Shakespeare Place Sydney New South Wales Australia Agenda: To consider the re-election and appointment of Directors.공시 • Aug 22Race Oncology Limited Announces Board ChangesRace Oncology Limited announced changes to the Board and Management team structure, to ensure the company and its lead asset, bisantrene, are suitably positioned for clinical success. Effective immediately, Dr. Peter Smith will step into the role of Executive Director, taking over from Damian Clarke-Bruce, who has tendered his resignation. Non-Executive Director, Dr. John Cullity has advised his intention to retire from the Race Board, following a long and productive tenure.공시 • Jun 29Race Oncology Limited Announces Board ChangesRace Oncology Limited announced the appointment of Dr Peter Smith as a Non-Executive Director, replacing Daniel Sharp who has advised his resignation to concentrate on other personal and professional interests. Dr Peter (Pete) Smith has over 30 years of experience in a broad range of activities in the healthcare industry with a strong focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He is currently CEO of private company, Myrio Therapeutics (formerly Affinity Bio.) Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD (later acquired by CSL.) Prior to moving to Australia, Pete co-founded and was CFO of Onyvax Ltd, a cancer immune-therapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC and was involved in numerous transactions including IPOs, fundraisings and M&A. His undergraduate degree and PhD are from the University of Cambridge, the latter in the field of cell-signalling. He is currently also a Director of private companies, Hula Therapeutics and Amala Therapeutics.공시 • May 09Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023Race Oncology announced the appointment of Dr. Michelle Rashford as Chief Medical Officer (CMO), taking over from Interim CMO, Dr. Ajay Duggal. Dr. Rashford is an internationally experienced biopharmaceutical executive and former physician, with expertise in the successful development and commercialisation of pharmaceuticals across oncology, virology, and immunology. Her 25+ years of drug development experience spans large pharmaceuticals to smaller biotech companies and includes pre-clinical and clinical development, medical and regulatory affairs, and drug commercialisation. Dr. Rashford will join Race Oncology on 1 July 2023 from the Japanese Pharmaceutical company Kyowa Kirin, where she has been the Head of Global Clinical Sciences. Prior to her role at Kyowa Kirin, Dr. Rashford was the Senior Vice President of Clinical Science at Adlai Nortye Biopharma, where she successfully grew the US Clinical Development team and prepared for the company's Phase III trial. She has also held senior roles within global pharmaceutical companies, including five years at Bristol-Myers Squibb and close to 20 years at Roche in a variety of national and global clinical development roles. Dr. Rashford holds a Bachelor of Medicine & Bachelor of Surgery from the University of Tasmania, Australia.공시 • Feb 02Race Oncology Limited Appoints Damian Clarke-Bruce as DirectorRace Oncology Limited announced the appointment of Damian Clarke-bruce as Director. Date of appointment is February 1, 2023.공시 • Feb 01Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer TrialRace Oncology Limited announced it has received human ethics approval from the Hunter New England Human Research Ethics Committee(NSW, Australia) for the observational stage of a planned Phase 1/2b clinical trial of Zantrene (bisantrene dihydrochloride) in breast cancer patients, to be treated with doxorubicin and cyclophosphamide and who have two or more cardiovascular risk factors. Details of the trial design and purposes have been previously described. Before patients can be enrolled and treated Race must first submit and then receive research institutional governance (site budget and contracting) approval. Submission is expected to take place in the coming weeks. Governance approval is typically received within 4 to 8 weeks of submission. The study will recruit and monitor up to 50 patients being treated for breast cancer using the standard of care (SoC) regimen of doxorubicin (Adriamycin®) and cyclophosphamide - referred to as "AC chemotherapy". The aim of this study is to identify the rate and level of heart damage caused by AC chemotherapy, using modern advanced cardiac imaging and biochemical methods. In addition, the anti-cancer efficacy of AC chemotherapy will be monitored using a liquid biopsy (DNA) approach. The data from this study will be directional for the design of a subsequent Phase 1/2b interventional trial that may help patients to avoid the permanent heart damage that can be caused by AC chemotherapy as well as potentially improving anti-cancer outcomes. These human trials are fully funded from capital raised in December 2021.공시 • Jan 19Race Oncology Limited, Annual General Meeting, Feb 21, 2023Race Oncology Limited, Annual General Meeting, Feb 21, 2023, at 10:30 AUS Eastern Standard Time. Location: Race Oncology Limited, Level 36, Gateway Building, 1 Macquarie Place, Sydney NSW 2000 Sydney New South Wales Australia Agenda: To consider and approve issue of options to director - Danny Sharp; to approve issue of options to director Damian Clarke-Bruce; to approve issue of options to director Mary Harney; to approve the increase in total aggregate remuneration for non-executive directors; to consider other matters if any.이익 및 매출 성장 예측OTCPK:RAON.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202711-7-6-616/30/20263-27-27-2716/30/20255-6-6-616/30/20244-14-10-10N/A3/31/20245-12-11-11N/A12/31/20236-11-13-13N/A9/30/20234-11-12-12N/A6/30/20233-10-11-11N/A3/31/20232-10-10-10N/A12/31/20221-11-9-9N/A9/30/20221-11-8-8N/A6/30/20221-11-6-6N/A3/31/20221-10-6-6N/A12/31/20211-9-6-6N/A9/30/20211-8-5-5N/A6/30/20210-6-5-5N/A3/31/20210-5-4-4N/A12/31/20200-4-3-3N/A9/30/20200-4-3-3N/A6/30/20200-4-2-2N/A3/31/20200-3-2-2N/A12/31/20190-3-2-2N/A9/30/20190-3-2-2N/A6/30/20190-4-3-3N/A3/31/20190-4-3-3N/A12/31/20180-5-3-3N/A9/30/20180-6-3-3N/A6/30/20180-6-4-4N/A3/31/20180-6N/A-4N/A12/31/20170-6N/A-4N/A9/30/20170-5N/A-3N/A6/30/2017N/A-4N/A-2N/A3/31/2017N/A-3N/A-2N/A12/31/2016N/A-2N/A-1N/A9/30/2016N/A-1N/A-1N/A6/30/2016N/A0N/A0N/A3/31/2016N/A0N/A0N/A12/31/2015N/A0N/A0N/A9/30/2015N/A0N/A0N/A6/30/2015N/A0N/A0N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: RAON.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: RAON.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: RAON.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: RAON.F 의 수익(연간 34.8%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: RAON.F 의 수익(연간 34.8%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: RAON.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/10/08 12:18종가2024/07/11 00:00수익2024/06/30연간 수익2024/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Racura Oncology Ltd는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullIndependent Investment Research (Aust.) Pty LtdChris KallosMST Financial Services Pty Limited
공시 • May 05Race Oncology Limited Announces Change of Chief Medical Officer, Effective May 5, 2025Race Oncology Limited announced the appointments of Dr. Jose Iglesias, who succeeds Dr. Michelle Rashford as Chief Medical Officer (CMO), effective 5 May 2025. Dr. Jose Iglesias is an internationally recognized pharmaceutical executive with a distinguished career spanning both major and emerging pharmaceutical companies. His appointment marks a significant addition to Race's clinical leadership team. Dr. Iglesias held key leadership roles at Abraxis BioScience, including Vice President of Global Clinical Development and Chief Medical Officer, where he oversaw the global development of the reformulated chemotherapeutic agent, Abraxane® (paclitaxel) and other pipeline assets. He later served as Vice President of Clinical Development at Celgene, successfully leading several Phase 3 clinical programs for Abraxane® in pancreatic, lung, and metastatic breast cancers. Dr. Iglesias has also held senior medical leadership roles at Amgen, Bionomics, Biothera Pharmaceuticals, Apobiologix, and Eli Lilly, including as Head of Clinical Studies at Eli Lilly Australia. His has extensive experience interacting with global regulatory authorities, reimbursement agencies, oncology cooperative groups, and patient advocacy organizations. He serves as an independent oncology consultant, specializing in solid tumour oncology, immuno-oncology, and translational medicine, with a focus on early to mid-phase clinical development. A widely published expert in oncology, Dr. Iglesias's work has garnered over 12,000 citations.
공시 • Apr 03Race Oncology Limited Announces RC220 Phase 1 Trial Opens for Patient EnrolmentRace Oncology Limited (Race) announced the site activation of Southside Cancer Care Centre (Miranda, NSW) after receiving governance approval enabling the commencement of patient enrolment for its Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumours patients. This follows the receipt of human ethics approval, undertaking site initiation, and completion of all documentation. The Phase 1 trial will be open label and conducted across multiple sites in Australia, Hong Kong and South Korea. The trial will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose (MTCD) in combination with doxorubicin, and effects on a range of clinical biomarkers including m6A RNA. After an interim analysis of the data, the optimal dosage of RC220 in combination with doxorubicin will be assessed in an additional 20 patients for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. The Phase 1 trial will use a Bayesian design enabling greater trial flexibility and speed than traditional approaches. A recent meta-analysis of single agent doxorubicin treatment undertaken by Race Oncology has identified an anticancer response rate to doxorubicin of up to 35% in a wide range of advance and metastatic solid tumour cancers including breast cancer, small cell lung cancer, ovarian cancer, bladder cancer, liver cancer, endometrial cancer, upper gastrointestinal cancer, thyroid cancer, non-small cell lung cancer, and prostate cancer. Preclinical studies by Race Oncology have identified enhancement of the cancer killing activity of doxorubicin by the active anticancer agent in RC220 in 85% of 143 diverse cancer cell lines screened. Timing of first patient enrolment is subject to patient suitability and their interest in participating in the trial.
공시 • Mar 31Race Oncology Limited Receives HREC Approval from Bellberry to Commence its RC220 Phase 1 Clinical Trial at Gosford and Wyong HospitalsRace Oncology Limited announced that it has received HREC approval from Bellberry to commence its RC220 Phase 1 clinical trial at Gosford and Wyong Hospitals (Central Coast Local Health District). HREC approval allows both the Gosford and Wyong Hospitals to enrol patients subject to final site approvals and activation. These approvals are expected during the month of April. The RAC-010 clinical trial is designed to assess the safety, tolerability and pharmacokinetics (PK) of RC220 alone and in combination with doxorubicin, in patients with solid tumours. This approval follows recent HREC approval for the Southside Cancer Centre (Miranda). It is expected HREC approval will be received for additional trial sites in Australia, Hong Kong and South Korea over the following months.
공시 • Oct 07Race Oncology Limited, Annual General Meeting, Nov 25, 2024Race Oncology Limited, Annual General Meeting, Nov 25, 2024. Location: at the dixon room, state library nsw, 1 shakespeare place, new south wales, australia., sydney Australia
공시 • Nov 22Race Oncology Limited Appoints Daniel Tillett as Chief Executive OfficerRace Oncology Limited announced that Dr Daniel Tillett has been appointed full-time Chief Executive Officer, effective immediately. Dr Tillett will work alongside Executive Director, Dr Pete Smith, to advance the Company's strategic, clinical and commercialization plans for bisantrene. From September 2019 to March 2023, Dr Tillett was Race's Chief Scientific Officer and Executive Director. He has most recently been working with the Company in a consultancy capacity. In addition to his extensive experience with Race and bisantrene, Dr Tillett brings more than 25 years of experience in the biotech industry and is the founder and CEO of Nucleics, an Australian biotechnology company focused on DNA sequencing and genomics. He was a tenured academic (Senior Lecturer) within the School of Pharmacy and Applied Science at La Trobe University, Australia teaching and researching in the areas of phage therapy (bacterial virology), pharmacy, environmental microbiology, bioinformatics and cancer.
공시 • Oct 10Race Oncology Limited, Annual General Meeting, Nov 27, 2023Race Oncology Limited, Annual General Meeting, Nov 27, 2023, at 12:00 AUS Eastern Standard Time. Location: the Dixon Room, State Library NSW, 1 Shakespeare Place Sydney New South Wales Australia Agenda: To consider the re-election and appointment of Directors.
공시 • Aug 22Race Oncology Limited Announces Board ChangesRace Oncology Limited announced changes to the Board and Management team structure, to ensure the company and its lead asset, bisantrene, are suitably positioned for clinical success. Effective immediately, Dr. Peter Smith will step into the role of Executive Director, taking over from Damian Clarke-Bruce, who has tendered his resignation. Non-Executive Director, Dr. John Cullity has advised his intention to retire from the Race Board, following a long and productive tenure.
공시 • Jun 29Race Oncology Limited Announces Board ChangesRace Oncology Limited announced the appointment of Dr Peter Smith as a Non-Executive Director, replacing Daniel Sharp who has advised his resignation to concentrate on other personal and professional interests. Dr Peter (Pete) Smith has over 30 years of experience in a broad range of activities in the healthcare industry with a strong focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He is currently CEO of private company, Myrio Therapeutics (formerly Affinity Bio.) Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD (later acquired by CSL.) Prior to moving to Australia, Pete co-founded and was CFO of Onyvax Ltd, a cancer immune-therapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC and was involved in numerous transactions including IPOs, fundraisings and M&A. His undergraduate degree and PhD are from the University of Cambridge, the latter in the field of cell-signalling. He is currently also a Director of private companies, Hula Therapeutics and Amala Therapeutics.
공시 • May 09Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023Race Oncology announced the appointment of Dr. Michelle Rashford as Chief Medical Officer (CMO), taking over from Interim CMO, Dr. Ajay Duggal. Dr. Rashford is an internationally experienced biopharmaceutical executive and former physician, with expertise in the successful development and commercialisation of pharmaceuticals across oncology, virology, and immunology. Her 25+ years of drug development experience spans large pharmaceuticals to smaller biotech companies and includes pre-clinical and clinical development, medical and regulatory affairs, and drug commercialisation. Dr. Rashford will join Race Oncology on 1 July 2023 from the Japanese Pharmaceutical company Kyowa Kirin, where she has been the Head of Global Clinical Sciences. Prior to her role at Kyowa Kirin, Dr. Rashford was the Senior Vice President of Clinical Science at Adlai Nortye Biopharma, where she successfully grew the US Clinical Development team and prepared for the company's Phase III trial. She has also held senior roles within global pharmaceutical companies, including five years at Bristol-Myers Squibb and close to 20 years at Roche in a variety of national and global clinical development roles. Dr. Rashford holds a Bachelor of Medicine & Bachelor of Surgery from the University of Tasmania, Australia.
공시 • Feb 02Race Oncology Limited Appoints Damian Clarke-Bruce as DirectorRace Oncology Limited announced the appointment of Damian Clarke-bruce as Director. Date of appointment is February 1, 2023.
공시 • Feb 01Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer TrialRace Oncology Limited announced it has received human ethics approval from the Hunter New England Human Research Ethics Committee(NSW, Australia) for the observational stage of a planned Phase 1/2b clinical trial of Zantrene (bisantrene dihydrochloride) in breast cancer patients, to be treated with doxorubicin and cyclophosphamide and who have two or more cardiovascular risk factors. Details of the trial design and purposes have been previously described. Before patients can be enrolled and treated Race must first submit and then receive research institutional governance (site budget and contracting) approval. Submission is expected to take place in the coming weeks. Governance approval is typically received within 4 to 8 weeks of submission. The study will recruit and monitor up to 50 patients being treated for breast cancer using the standard of care (SoC) regimen of doxorubicin (Adriamycin®) and cyclophosphamide - referred to as "AC chemotherapy". The aim of this study is to identify the rate and level of heart damage caused by AC chemotherapy, using modern advanced cardiac imaging and biochemical methods. In addition, the anti-cancer efficacy of AC chemotherapy will be monitored using a liquid biopsy (DNA) approach. The data from this study will be directional for the design of a subsequent Phase 1/2b interventional trial that may help patients to avoid the permanent heart damage that can be caused by AC chemotherapy as well as potentially improving anti-cancer outcomes. These human trials are fully funded from capital raised in December 2021.
공시 • Jan 19Race Oncology Limited, Annual General Meeting, Feb 21, 2023Race Oncology Limited, Annual General Meeting, Feb 21, 2023, at 10:30 AUS Eastern Standard Time. Location: Race Oncology Limited, Level 36, Gateway Building, 1 Macquarie Place, Sydney NSW 2000 Sydney New South Wales Australia Agenda: To consider and approve issue of options to director - Danny Sharp; to approve issue of options to director Damian Clarke-Bruce; to approve issue of options to director Mary Harney; to approve the increase in total aggregate remuneration for non-executive directors; to consider other matters if any.